Ironwood Pharma (IRWD) Stock Statistics & Valuation Metrics

Ironwood Pharma has a market cap or net worth of $311.87M. The enterprise value is ―.

Ironwood Pharma has 162,434,130 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ironwood Pharma’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 0.40%.

The current PE Ratio of Ironwood Pharma is ―. Ironwood Pharma’s PEG ratio is -8.00.

In the last 12 months, Ironwood Pharma had revenue of 351.41M and earned 880.00K in profits. Earnings per share was 0.01.

In the last 12 months, operating cash flow was 67.68M and capital expenditures -35.00K, giving a free cash flow of 67.65M billion.

Ironwood Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Ironwood Pharma upcoming earnings date is Feb 12, 2026, Before Open (Confirmed).

Ironwood Pharma as a current ratio of 4.69, with Debt / Equity ratio of -377.78%

In the past 12 months, Ironwood Pharma has paid 64.32M in taxes.

Ironwood Pharma EV to EBITDA ratio is 12.13, with an EV/FCF ratio of 11.76.

Ironwood Pharma has $140.41M in cash and marketable securities with $213.24M in debt, giving a net cash position of -$72.83M billion.

Gross margin is 63.71%, with operating margin of 26.50%, and net profit margin of 0.25%.

The average price target for Ironwood Pharma is ―, which is 11.43% higher than the current price. The consensus rating is Hold